Skip to main content
logo
Cardinal Health, Inc. (CAH)
NYSE: CAH · Real-Time Price · USD
251.09
+6.33 (2.59%)
At close: Oct 29, 2026, 4:00 PM EDT
252.07
+0.98 (0.39%)
After-hours: Oct 29, 2026, 7:48 PM EDT

Cardinal Health Revenue by Segment

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016
Pharmaceutical
378.81B375.36B369.68B215.84B204.62B204.83B205.05B207.77BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Pharmaceutical Growth
85.12%83.25%80.29%3.88%-2.92%-0.02%2.00%6.45%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Medical
22.10B22.17B22.18B12.74B12.68B12.59B12.55B13.27BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Medical Growth
74.22%76.05%76.80%-3.99%-8.82%-13.49%-17.07%-11.49%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Profit by Segment

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016
Pharmaceutical
4.35B4.24B4.12B2.40B2.26B2.21B2.12B2.11BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Pharmaceutical Growth
92.83%92.47%94.16%13.51%8.19%4.55%-0.28%1.69%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Medical
840.00M760.00M774.00M657.00M135.00M112.00M93.00M146.00MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Medical Growth
522.22%578.57%732.26%350.00%-35.41%-54.10%-61.89%-23.16%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Profit Margin by Segment

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016
Medical
8.105.505.945.434.253.562.974.22UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Pharmaceutical
4.734.594.504.444.414.324.164.09UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Operating Expense Breakdown

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016
Distribution, Selling, General, and Administrative
6.13B5.99B5.76B5.57B5.38B5.18B5.14B5.12BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Distribution, Selling, General, and Administrative Growth
13.94%15.77%12.10%8.73%6.81%2.90%4.38%5.90%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Amortization and Other Acquisition-Related Costs
469.00M481.00M519.00M494.00M464.00M408.00M336.00M294.00MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Amortization and Other Acquisition-Related Costs Growth
1.08%17.89%54.46%68.03%63.38%47.83%24.44%5.76%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Impairments and (Gain)/Loss on Disposal of Assets, Net
177.00M206.00M4.00M21.00M18.00M-7.00M94.00M92.00MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Impairments and (Gain)/Loss on Disposal of Assets, Net Growth
883.33%--95.74%-77.17%-97.14%--89.84%-94.37%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Restructuring and Employee Severance
106.00M93.00M96.00M84.00M88.00M130.00M155.00M174.00MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Restructuring and Employee Severance Growth
20.45%-28.46%-38.06%-51.72%-49.71%-6.47%51.96%91.21%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Litigation Charges, Net
-10.00M-16.00M-132.00M-145.00M-185.00M-126.00M60.00M80.00MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade